Alcohol and Drug Abuse Research Center
Center for Depression, Anxiety and Stress Research
McLean Imaging Center
Clinical Unit Based Research
Mailman Research Center
Shervert H. Frazier Research Institute
Clinical Trials
Inventions for License
Research News


MCL 3482.0: Natural Product Extracts to Treat HIV Infection

Mario Canki, David Lee, et al.

Background and Description

In spite of considerable success in developing drugs to combat the human immunodeficiency virus (HIV-l), the effectiveness of existing antiretroviral (ART) therapies is limited by mutation and increasing drug resistance. It has been found that approximately 20% of all new HIV-1 infections are resistant to the currently available drugs. Consequently, concerted efforts toward the discovery and development of novel inhibitors of HIV-1 infection and replication must persist if continued viral repression and virus eradication are to be achieved. Products derived from natural sources have been shown to inhibit HIV-1 replication during various stages of the virus life cycle and represent a potential source of novel therapeutic agents.

Potential Commercial Uses

The methods and compositions, of the invention feature a natural product extract, or purified components thereof, for the treatment of HIV-1 and other viral infections. The natural products of the invention include brown algae, specifically algae of the Sargassum fusiforme species. The inventors have shown that aqueous extracts from S. fusiforme blocked HIV-1 infection and replication by over 90% in T cells, human macrophages and microglia, and also inhibited pseudotyped HIV-1 (VSV/NL4-3) infection in human astrocytes by over 70%. Inhibition was mediated against both CXCR4 (X4) and CCR5 (R5)-tropic HIV-1, was dose dependent and long lasting, did not inhibit cell growth or viability, was not toxic to cells, and was comparable to inhibition by the nucleoside analogue 2', 3'-didoxycytidine (ddC). S. fusiforme treatment blocked direct cell-to-cell infection spread. The inventors have begun to characterize the active components of these extracts, and have identified specific compounds which appear to have antiviral activity.

Publication and Patent Status

McLean Hospital and Albany Medical College are the owners of a pending U.S. patent application claiming this invention. Aspects of this work have been published in Paskaleva et al., AIDS Res Ther 3: 15 (2006).

Licenses Available

McLean Hospital and Albany Medical College are offering a worldwide exclusive license to this technology.

For more information, please contact:

David J. Glass, Ph.D.
Senior Associate Director, Technology Transfer
McLean Hospital Research Administration
115 Mill Street
Belmont, MA 02478-9106
(617) 855-3825 - tel
(617) 855-3745 - fax